한글목차

아지트로마이신 이수화물 세계 시장은 2024년 4,440톤으로 평가되고 2035년에는 8,280톤에 달할 것으로 예상되며, 예측 기간 동안 5.89%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다.

아지트로마이신의 유도체인 아지트로마이신 이수화물은 광범위한 항균 활성으로 인해 제약 산업에서 중요한 역할을 하고 있습니다. 호흡기 감염, 피부 감염, 성병 등의 치료에 널리 사용되고 있습니다. 이 시장의 주요 원동력은 세계 헬스케어에 대한 인식 증가, 세균성 감염의 유병률 증가, 특히 신흥 경제권에서 저렴한 치료 옵션의 필요성 등이며, 2022년 EU 산업 R&D 투자 스코어보드에 따르면 의료 산업은 2021년에 약 2,353억 유로를 연구개발(R&D)에 할당했습니다. 이는 전 세계 기업 R&D 지출의 21.5%에 해당합니다.

지역적으로 북미와 유럽은 선진화된 의료 인프라와 약물 내성 감염의 확산으로 인해 아지트로마이신 이수화물의 수요를 주도하고 있습니다. 그러나 아시아태평양은 의료 서비스 접근성 개선, 인구 증가, 세균 감염률 증가로 인해 가장 빠른 성장이 예상됩니다. 또한, 온라인 약국 및 E-Commerce 플랫폼의 확대로 인해 의료 인프라가 제한된 지역에서 아지트로마이신 이수화물의 접근성이 개선되고 있습니다.

시장은 또한 아지트로마이신 이수화물의 제형 및 전달에 대한 기술 혁신을 목격하고 있으며, 여기에는 약물의 효능과 환자 순응도를 향상시키는 새로운 제형 및 병용요법의 개발이 포함됩니다. 또한, 특허 만료로 인한 제네릭 의약품의 증가로 아지트로마이신 이수화물의 가격이 저렴해져 더 많은 환자들이 쉽게 접근할 수 있게 되었습니다. 그러나 규제의 복잡성, 항균제 내성의 출현, 특정 지역에서 더 나은 대체품의 필요성과 같은 도전과제는 시장 성장을 저해할 수 있습니다. 이러한 과제에도 불구하고 아지트로마이신 이수화물 세계 시장은 지속적인 의료 수요와 의약품 개발의 발전으로 인해 지속적으로 성장할 것으로 예상됩니다.

주요 시장 촉진요인

세균 감염 증가

주요 시장 과제

규제 장벽과 시장 접근성

주요 시장 동향

온라인 약국 및 E-Commerce 플랫폼의 성장

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 아지트로마이신 이수화물 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 제품별(API 등급 아지트로마이신 이수화물, 의약품 등급 아지트로마이신 이수화물, 연구 등급 아지트로마이신 이수화물)
  • 용도별(항생제, 호흡기 감염증, 성감염증, 피부 감염증)
  • 기업별(2024년)
  • 지역별
• 시장 맵

제6장 북미의 아지트로마이신 이수화물 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 멕시코
  • 캐나다

제7장 유럽의 아지트로마이신 이수화물 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 아지트로마이신 이수화물 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 아지트로마이신 이수화물 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 아지트로마이신 이수화물 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병(있는 경우)
• 제품 발매(있는 경우)
• 최근 동향

제13장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 능력
• 고객의 능력
• 대체품의 위협

제14장 경쟁 구도

• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Sandoz International GmbH
• Arbindo Pharma Limited
• Mylan N.V.

제15장 전략적 제안

제16장 조사 회사 소개 및 면책사항

영문목차

The Global Azithromycin Dihydrate Market was valued at 4.44 thousand tonnes in 2024 and is projected to reach 8.28 thousand tonnes by 2035, growing at a compound annual growth rate (CAGR) of 5.89% during the forecast period.

Azithromycin dihydrate, a derivative of azithromycin, plays a critical role in the pharmaceutical industry due to its broad-spectrum antimicrobial activity. It is widely used in the treatment of respiratory, skin, and sexually transmitted infections, among others. This market is primarily driven by increasing global healthcare awareness, the rising incidence of bacterial infections, and the need for affordable treatment options, especially in emerging economies. According to the 2022 EU Industrial R&D Investment Scoreboard, the health industry allocated approximately €235.3 billion to research and development (R&D) in 2021, which represented 21.5% of global business R&D expenditure.

Geographically, North America and Europe are leading the demand for azithromycin dihydrate, owing to their advanced healthcare infrastructure and the growing prevalence of drug-resistant infections. However, the Asia-Pacific region is expected to experience the fastest growth, driven by improving healthcare access, a growing population, and increasing rates of bacterial infections. Moreover, the expansion of online pharmacies and e-commerce platforms has improved access to azithromycin dihydrate in regions with limited healthcare infrastructure.

The market is also witnessing innovations in the formulation and delivery of azithromycin dihydrate, including the development of new dosage forms and combination therapies that enhance the drug's efficacy and patient compliance. Additionally, the increasing availability of generics, due to patent expirations, is making azithromycin dihydrate more affordable and accessible to a wider patient population. However, challenges such as regulatory complexities, the emergence of antimicrobial resistance, and the need for better alternatives in certain regions may hinder market growth. Despite these challenges, the Global Azithromycin Dihydrate Market is expected to continue its expansion due to ongoing medical demand and advancements in drug development.

Key Market Drivers

Rising Incidence of Bacterial Infections

The increasing prevalence of bacterial infections is one of the major drivers of the Global Azithromycin Dihydrate Market. With global population growth and urbanization, the spread of infectious diseases is becoming more widespread. Respiratory infections, including pneumonia, bronchitis, and sinusitis, are common conditions treated with azithromycin, which is known for its broad-spectrum antibiotic properties. Azithromycin dihydrate's effectiveness against a wide range of bacterial pathogens makes it a critical treatment option. The growing number of bacterial infections, particularly in emerging economies with expanding healthcare systems, is increasing demand for antibiotics such as azithromycin dihydrate. Furthermore, environmental factors such as rising air pollution are contributing to higher rates of respiratory infections, further driving the market need for azithromycin. Antibiotic resistance remains a growing global concern, and azithromycin dihydrate's ability to treat multi-drug-resistant organisms reinforces its role in the global healthcare system. This rising burden of bacterial infections continues to support market growth.

Key Market Challenges

Regulatory Barriers and Market Access

A significant challenge facing the Global Azithromycin Dihydrate Market is the complex and varied regulatory requirements across different regions. Regulatory authorities such as the U.S. FDA, EMA, and other local agencies have stringent standards for approval, including Good Manufacturing Practices (GMP) compliance and safety guidelines. Prolonged approval timelines can delay market entry and slow the pace of innovation. Moreover, increasing regulatory focus on antibiotic resistance and usage has led to stricter guidelines for azithromycin dihydrate's application. For instance, the Central Drug Standard Control Organisation (CDSCO) in India has flagged several batches of azithromycin dihydrate for not meeting quality standards. These regulatory hurdles can impede market access, affecting both the speed of innovation and competition in the market.

Key Market Trends

Growth of Online Pharmacies and E-commerce Platforms

The rise of online pharmacies and e-commerce platforms has become a key driver of the Global Azithromycin Dihydrate Market. With the increasing popularity of digital health services, patients now have greater access to medications such as azithromycin dihydrate through online pharmacies. This has revolutionized the pharmaceutical sector, especially in regions where traditional pharmacies are scarce or hard to reach. The convenience of online shopping, alongside the ability to compare prices and read reviews, has made it easier for consumers to obtain azithromycin dihydrate from trusted online sources, expanding its reach. Additionally, e-commerce platforms offer home delivery services, a benefit especially appreciated during the COVID-19 pandemic when patients preferred to avoid in-person pharmacy visits. Online pharmacies also offer competitive pricing, which is particularly advantageous in developing regions where affordability is critical. The growth of telemedicine further contributes to this trend, as virtual consultations with healthcare providers often result in prescriptions for antibiotics like azithromycin dihydrate that patients can easily order online. As digital infrastructure improves, the accessibility of azithromycin dihydrate through online platforms will continue to increase, driving market growth.

Key Market Players

• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Sandoz International GmbH
• Arvindo Pharma Limited
• Mylan N.V.

Report Scope

In this report, the Global Azithromycin Dihydrate Market has been segmented as follows:

By Product:

• API Grade Azithromycin Dihydrate
• Pharmaceutical Grade Azithromycin Dihydrate
• Research Grade Azithromycin Dihydrate

By Application:

• Antibiotics
• Respiratory Infections
• Sexually Transmitted Diseases
• Skin Infections

By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

• Company Profiles: In-depth analysis of major players in the Global Azithromycin Dihydrate Market.

Available Customizations

TechSci Research offers customization options for the Global Azithromycin Dihydrate Market report based on specific company needs. Customization options include:

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Azithromycin Dihydrate Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (API Grade Azithromycin Dihydrate, Pharmaceutical Grade Azithromycin Dihydrate, Research Grade Azithromycin Dihydrate)
  • 5.2.2. By Application (Antibiotics, Respiratory Infections, Sexually Transmitted Diseases, Skin Infections)
  • 5.2.3. By Company (2024)
  • 5.2.4. By Region
• 5.3. Market Map

6. North America Azithromycin Dihydrate Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Azithromycin Dihydrate Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
  • 6.3.2. Mexico Azithromycin Dihydrate Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
  • 6.3.3. Canada Azithromycin Dihydrate Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application

7. Europe Azithromycin Dihydrate Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Azithromycin Dihydrate Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
  • 7.3.2. Germany Azithromycin Dihydrate Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Azithromycin Dihydrate Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Azithromycin Dihydrate Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Azithromycin Dihydrate Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application

8. Asia-Pacific Azithromycin Dihydrate Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Azithromycin Dihydrate Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
  • 8.3.2. India Azithromycin Dihydrate Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
  • 8.3.3. South Korea Azithromycin Dihydrate Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
  • 8.3.4. Japan Azithromycin Dihydrate Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Azithromycin Dihydrate Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application

9. South America Azithromycin Dihydrate Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Azithromycin Dihydrate Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Azithromycin Dihydrate Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Azithromycin Dihydrate Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application

10. Middle East and Africa Azithromycin Dihydrate Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Azithromycin Dihydrate Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Azithromycin Dihydrate Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Azithromycin Dihydrate Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Pfizer Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Teva Pharmaceutical Industries Ltd.
• 14.3. Sandoz International GmbH
• 14.4. Arbindo Pharma Limited
• 14.5. Mylan N.V.

15. Strategic Recommendations

16. About Us & Disclaimer